- Home
- FAAS vs ESLA Comparison
FAAS vs ESLA Comparison
Compare FAAS & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- ESLA
- Stock Information
- Founded
- FAAS 2021
- ESLA 2021
- Country
- FAAS Indonesia
- ESLA United States
- Employees
- FAAS N/A
- ESLA N/A
- Industry
- FAAS
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FAAS
- ESLA Health Care
- Exchange
- FAAS NYSE
- ESLA Nasdaq
- Market Cap
- FAAS 34.6M
- ESLA 37.3M
- IPO Year
- FAAS N/A
- ESLA N/A
- Fundamental
- Price
- FAAS $0.54
- ESLA $0.99
- Analyst Decision
- FAAS
- ESLA Strong Buy
- Analyst Count
- FAAS 0
- ESLA 1
- Target Price
- FAAS N/A
- ESLA $16.00
- AVG Volume (30 Days)
- FAAS 304.0K
- ESLA 139.9K
- Earning Date
- FAAS 09-17-2024
- ESLA 03-18-2025
- Dividend Yield
- FAAS N/A
- ESLA N/A
- EPS Growth
- FAAS N/A
- ESLA N/A
- EPS
- FAAS N/A
- ESLA N/A
- Revenue
- FAAS $57,730,593.00
- ESLA N/A
- Revenue This Year
- FAAS N/A
- ESLA N/A
- Revenue Next Year
- FAAS N/A
- ESLA N/A
- P/E Ratio
- FAAS N/A
- ESLA N/A
- Revenue Growth
- FAAS 38.16
- ESLA N/A
- 52 Week Low
- FAAS $0.38
- ESLA $0.63
- 52 Week High
- FAAS $12.97
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- FAAS 46.84
- ESLA 41.26
- Support Level
- FAAS $0.50
- ESLA $0.89
- Resistance Level
- FAAS $0.57
- ESLA $1.78
- Average True Range (ATR)
- FAAS 0.08
- ESLA 0.20
- MACD
- FAAS 0.00
- ESLA -0.03
- Stochastic Oscillator
- FAAS 38.81
- ESLA 11.01
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.